Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.43 |
| ▸ | ACLY | P53396 | 4/20 | 0.39 |
| ▸ | CPT2 | P23786 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gluconic Acid SCHEMBL28106011 | 1.00 | PDE4A (0.66) | PDE4AALDH1A1LMNAUSP2SLCO1B1 | |
| Mucic Acid SCHEMBL28083215 | 0.98 | PDE4A (0.63) | PDE4AALDH1A1LMNAUSP2SLCO1B1 | |
| Citric Acid SCHEMBL10438268 | 0.98 | PDE4A (0.63) | PDE4AALDH1A1LMNAUSP2SLCO1B1 | |
| Citric Acid SCHEMBL9052947 | 0.98 | PDE4A (0.63) | PDE4AALDH1A1LMNAUSP2SLCO1B1 | |
| Citric Acid SCHEMBL301965 | 0.98 | PDE4A (0.63) | PDE4AALDH1A1LMNAUSP2SLCO1B1 | |
| Citric Acid SCHEMBL10802994 | 0.97 | PDE4A (0.61) | PDE4AALDH1A1LMNAUSP2SLCO1B1 | |
| Citric Acid SCHEMBL17513691 | 0.94 | PDE4A (0.58) | PDE4AALDH1A1LMNAUSP2SLCO1B1 | |
| Citric Acid SCHEMBL301655 | 0.94 | PDE4A (0.58) | PDE4AALDH1A1LMNAUSP2SLCO1B1 | |
| Gluconic Acid SCHEMBL20876306 | 0.94 | PDE4A (0.58) | PDE4AALDH1A1LMNAUSP2SLCO1B1 | |
| Gluconic Acid SCHEMBL27650807 | 0.94 | PDE4A (0.58) | PDE4AALDH1A1LMNAUSP2SLCO1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114931589-A | Preparation method and application of platelet-rich plasma-derived exosome product | 苏州大学附属第一医院 | 2022-08-23 | — | — | CN | claimed |
| US-20160151415-A1 | PHARMACEUTICAL COMPOSITION FOR IMPROVING HEALTH, CURE ABNORMALITIES AND DEGENERATIVE DISEASE, ACHIEVE ANTI-AGING EFFECT OF THERAPY AND THERAPEUTIC EFFECT ON MAMMALS AND METHOD THEREOF | VECTOR VITALE LLC | 2016-06-02 | — | — | US | claimed |
| EP-1699302-B1 | CALCIUM-FORTIFIED PROTEIN-BASED BEVERAGE CONTAINING CALCIUM (LACTATE) GLUCONATE CITRATE | PURAC BIOCHEM BV (NL) | 2007-11-14 | — | — | EP | claimed |
| US-12011458-B2 | Pharmaceutical composition for improving health, cure abnormalities and degenerative disease, achieve anti-aging effect of therapy and therapeutic effect on mammals and method thereof | VECTOR VITALE IP LLC (US) | 2024-06-18 | — | — | US | disclosed |
| CN-115558243-B | Friction modified epoxy resin composite material, preparation method thereof and friction structure | 富地润滑科技股份有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-116249559-A | Anti-idiotype compositions and methods of use thereof | 埃克苏马生物技术公司 | 2023-06-09 | — | — | CN | disclosed |
| CN-116057181-A | Methods and compositions for modifying and delivering lymphocytes | 埃克苏马生物技术公司 | 2023-05-02 | — | — | CN | disclosed |
| US-20230061538-A1 | PHARMACEUTICAL COMPOSITION FOR IMPROVING HEALTH, CURE ABNORMALITIES AND DEGENERATIVE DISEASE, ACHIEVE ANTI-AGING EFFECT OF THERAPY AND THERAPEUTIC EFFECT ON MAMMALS AND METHOD THEREOF | VECTOR VITALE IP LLC (US) | 2023-03-02 | — | — | US | disclosed |
| CN-115243713-A | Methods and compositions for delivering modified lymphocyte aggregates | 埃克苏马生物技术公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-114931589-A | Preparation method and application of platelet-rich plasma-derived exosome product | 苏州大学附属第一医院 | 2022-08-23 | — | — | CN | disclosed |
| CN-114931589-A | Preparation method and application of platelet-rich plasma-derived exosome product | 苏州大学附属第一医院 | 2022-08-23 | — | — | CN | disclosed |
| US-20040132763-A1 | Amonafide salts | XANTHUS LIFE SCIENCES, INC. | 2004-07-08 | — | — | US | disclosed |
| US-6693198-B2 | Amonafide salts | XANTHUS LIFE SCIENCES, INC. (CA) | 2004-02-17 | — | — | US | disclosed |
| US-20030203932-A1 | Amonafide salts | XANTHUS LIFE SCIENCES, INC. (CA) | 2003-10-30 | — | — | US | disclosed |
| WO-2003089415-A1 | AMONAFIDE SALTS | XANTHUS LIFE SCIENCES, INC. (CA) | 2003-10-30 | — | — | WO | disclosed |
| JP-2001129507-A | ADDITIVE COMPOSITION FOR UNDERGROUND WATER BARRIER WALL AND CONSTRUCTION METHOD FOR CONTINUOUSLY INTEGRATED UNDERGROUND WATER BARRIER WALL SOLID BODY | LION CORP | 2001-05-15 | — | — | JP | disclosed |
| US-5302297-A | Adding carboxylic chelating agent to interfere with antiscaling agent and to precipitate inorganic salt which can then be separated | CREDIT SUISSE AG | 1994-04-12 | — | — | US | disclosed |
| US-4994461-A | Vasodilators; treating cardiovascular disorders | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1991-02-19 | — | — | US | disclosed |
| US-4876201-A | CULTURING WITH ALCALIGENES UNDER AEROBIC CONDITIONS | GENERAL ELECTRIC COMPANY (US) | 1989-10-24 | — | — | US | disclosed |
| US-4134890-A | 2-Aryl-2-[ω-(diisopropylamino)alkyl]-ω-(azabicycloalkyl)alkanamides | G. D. SEARLE & CO. (US) | 1979-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12011458-B2 | Pharmaceutical composition for improving health, cure abnormalities and degenerative disease, achieve anti-aging effect of therapy and therapeutic effect on mammals and method thereof | SLC25A20, CLN6, HTT | PDE4A 457/4885ALDH1A1 556/4885LMNA 453/4885 |
| US-20040132763-A1 | Amonafide salts | OR10J3, NR4A1, OGFR | PDE4A 3166/4885ALDH1A1 1438/4885LMNA 4566/4885 |
| US-20030203932-A1 | Amonafide salts | OR10J3, NR4A1, OGFR | PDE4A 3166/4885ALDH1A1 1438/4885LMNA 4566/4885 |
| US-20230061538-A1 | PHARMACEUTICAL COMPOSITION FOR IMPROVING HEALTH, CURE ABNORMALITIES AND DEGENERATIVE DISEASE, ACHIEVE ANTI-AGING EFFECT OF THERAPY AND THERAPEUTIC EFFECT ON MAMMALS AND METHOD THEREOF | SLC25A20, CLN6, HTT | PDE4A 457/4885ALDH1A1 556/4885LMNA 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.